|
1
|
Kono T, Shimoda M, Takahashi M, et al:
Immunohistochemical detection of the lymphatic marker podoplanin in
diverse types of human cancer cells using a novel antibody. Int J
Oncol. 31:501–508. 2007.PubMed/NCBI
|
|
2
|
Yan G, Zhou XY, Cai SJ, et al:
Lymphangiogenic and angiogenic microvessel density in human primary
sporadic colorectal carcinoma. World J Gastroenterol. 14:101–107.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Moreira LR, Schenka AA, Latuf-Filho P, et
al: Immunohistochemical analysis of vascular density and area in
colorectal carcinoma using different markers and comparison with
clinicopathologic prognostic factors. Tumour Biol. 32:527–534.
2011. View Article : Google Scholar
|
|
4
|
Ozcelik O, Haytac MC, Ergin M, Antmen B
and Seydaoglu G: The immunohistochemical analysis of vascular
endothelial growth factors A and C and microvessel density in
gingival tissues of systemic sclerosis patients: their possible
effects on gingival inflammation. Oral Surg Oral Med Oral Pathol
Oral Radiol Endod. 105:481–485. 2008. View Article : Google Scholar
|
|
5
|
Lee HW, Qin YX, Kim YM, et al: Expression
of lymphatic endothelium-specific hyaluronan receptor LYVE-1 in the
developing mouse kidney. Cell Tissue Res. 343:429–444. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kato Y, Kaneko MK, Kuno A, et al:
Inhibition of tumor cell-induced platelet aggregation using a novel
anti-podoplanin antibody reacting with its
platelet-aggregation-stimulating domain. Biochem Biophys Res
Commun. 349:1301–1307. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kato Y, Kaneko M, Sata M, Fujita N, Tsuruo
T and Osawa M: Enhanced expression of Aggrus (T1alpha/podoplanin),
a platelet-aggregation-inducing factor in lung squamous cell
carcinoma. Tumour Biol. 26:195–200. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yuan P, Temam S, El-Naggar A, et al:
Overexpression of podoplanin in oral cancer and its association
with poor clinical outcome. Cancer. 107:563–569. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kimura N and Kimura I: Podoplanin as a
marker for mesothelioma. Pathol Int. 55:83–86. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ordóñez NG: D2-40 and podoplanin are
highly specific and sensitive immunohistochemical markers of
epithelioid malignant mesothelioma. Hum Pathol. 36:372–380.
2005.PubMed/NCBI
|
|
11
|
Breiteneder-Geleff S, Soleiman A, Kowalski
H, et al: Angiosarcomas express mixed endothelial phenotypes of
blood and lymphatic capillaries: podoplanin as a specific marker
for lymphatic endothelium. Am J Pathol. 154:385–394. 1999.
View Article : Google Scholar
|
|
12
|
Roy S, Chu A, Trojanowski JQ and Zhang PJ:
D2-40, a novel monoclonal antibody against the M2A antigen as a
marker to distinguish hemangioblastomas from renal cell carcinomas.
Acta Neuropathol. 109:497–502. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shibahara J, Kashima T, Kikuchi Y, Kunita
A and Fukayama M: Podoplanin is expressed in subsets of tumors of
the central nervous system. Virchows Arch. 448:493–499. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mishima K, Kato Y, Kaneko MK, et al:
Podoplanin expression in primary central nervous system germ cell
tumors: a useful histological marker for the diagnosis of
germinoma. Acta Neuropathol. 111:563–568. 2006. View Article : Google Scholar
|
|
15
|
Mishima K, Kato Y, Kaneko MK, et al:
Increased expression of podoplanin in malignant astrocytic tumors
as a novel molecular marker of malignant progression. Acta
Neuropathol. 111:483–488. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fohn LE, Rodriguez A, Kelley MC, et al:
D2-40 lymphatic marker for detecting lymphatic invasion in thin to
intermediate thickness melanomas: association with sentinel lymph
node status and prognostic value-a retrospective case study. J Am
Acad Dermatol. 64:336–345. 2011. View Article : Google Scholar
|
|
17
|
Grimaldo S, Garcia M, Zhang H and Chen L:
Specific role of lymphatic marker podoplanin in retinal pigment
epithelial cells. Lymphology. 43:128–134. 2010.PubMed/NCBI
|
|
18
|
Schacht V, Dadras SS, Johnson LA, et al:
Up-regulation of the lymphatic marker podoplanin, a mucin-type
transmembrane glycoprotein, in human squamous cell carcinomas and
germ cell tumors. Am J Pathol. 166:913–921. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kitano H, Kageyama S, Hewitt SM, et al:
Podoplanin expression in cancerous stroma induces lymphangiogenesis
and predicts lymphatic spread and patient survival. Arch Pathol Lab
Med. 134:1520–1527. 2010.PubMed/NCBI
|
|
20
|
Wicki A, Lehembre F, Wick N, et al: Tumor
invasion in the absence of epithelial-mesenchymal transition:
podoplanin-mediated remodeling of the actin cytoskeleton. Cancer
Cell. 9:261–272. 2006. View Article : Google Scholar
|
|
21
|
Gurleyik G, Gurleyik E, Aker F, et al:
Lymphovascular invasion, as a prognostic marker in patients with
invasive breast cancer. Acta Chir Belg. 107:284–287.
2007.PubMed/NCBI
|
|
22
|
Carvalho FM, Zaganelli FL, Almeida BG, et
al: Prognostic value of podoplanin expression in intratumoral
stroma and neoplastic cells of uterine cervical carcinomas. Clinics
(Sao Paulo). 65:1279–1283. 2010. View Article : Google Scholar
|
|
23
|
Kreppel M, Krakowezki A, Kreppel B, et al:
Podoplanin expression in cutaneous head and neck squamous cell
carcinoma-prognostic value and clinicopathologic implications. J
Surg Oncol. 107:376–383. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Suzuki H, Onimaru M, Koga T, et al: High
podoplanin expression in cancer cells predicts lower incidence of
nodal metastasis in patients with lung squamous cell carcinoma.
Pathol Res Pract. 207:111–115. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Suzuki H, Onimaru M, Yonemitsu Y, et al:
Podoplanin in cancer cells is experimentally able to attenuate
prolymphangiogenic and lymphogenous metastatic potentials of lung
squamoid cancer cells. Mol Cancer. 9:2872010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shimizu K, Funai K, Sugimura H, et al:
D2-40-positive lymphatic vessel invasion is not a poor prognostic
factor in stage I lung adenocarcinoma. Pathol Int. 63:201–205.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rahadiani N, Ikeda J, Makino T, et al:
Tumorigenic role of podoplanin in esophageal squamous-cell
carcinoma. Ann Surg Oncol. 17:1311–1323. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tong L, Yuan S, Feng F and Zhang H: Role
of podoplanin expression in esophageal squamous cell carcinoma: a
retrospective study. Dis Esophagus. 25:72–80. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rudno-Rudzinska J, Kielan W, Grzebieniak
Z, et al: High density of peritumoral lymphatic vessels measured by
D2-40/podoplanin and LYVE-1 expression in gastric cancer patients:
an excellent prognostic indicator or a false friend? Gastric
Cancer. 16:513–520. 2013. View Article : Google Scholar
|
|
30
|
Herzog BH, Fu J, Wilson SJ, et al:
Podoplanin maintains high endothelial venule integrity by
interacting with platelet CLEC-2. Nature. 502:105–109. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Direkze NC and Alison MR: Bone marrow and
tumour stroma: an intimate relationship. Hematol Oncol. 24:189–195.
2006. View
Article : Google Scholar : PubMed/NCBI
|
